BBNX
Beta Bionics, Inc.29.63
-0.09-0.3%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Sales force ramp details clarified
Q&A revealed management's plan for at least 20 new sales territories in 2026—mostly front-half loaded—acknowledging current coverage of just half to a third of the addressable market amid an ideal 120-180 total, a deliberate ramp to match scaling systems. Guidance embeds pharmacy mix outperformance risk, which drags near-term revenue and gross margins despite strong retention; expect a sharper Q4-to-Q1 drop than last year sans prior tailwinds. Sean dismissed hypo concerns with trial-consistent data and a 'Tesla effect' narrative. Pharmacy adoption could exceed 36-38% via more plan deals; competitor entry aids momentum. Confident tone prevails, but investors will eye sales execution and Q1 softness.
Key Stats
Market Cap
1.30BP/E (TTM)
-Basic EPS (TTM)
-1.94Dividend Yield
0%Recent Filings
10-K
FY2025 results
Beta Bionics' 10-K for FY2025 ended December 31, 2025 lacks financial statements, revenue, profitability, or quarterly breakdowns, offering no insight into annual or Q4 results. No topline growth, margins, EPS, cash flow, debt, or capital allocation details appear. Non-GAAP metrics not disclosed in the 10-K. Directors snag $50,000 annual cash retainers plus RSUs worth $180,000 yearly. Filing skimps on numbers. Regulatory delays pose quarterly risks.
8-K
Q4 sales up 57%
Beta Bionics reported Q4 2025 net sales of $32.1 million, up 57% from $20.4 million in 2024, with full-year sales hitting $100.3 million, up 54%. PBP channel sales exploded 295% to $9.8 million while DME grew 24%; gross margin rose to 59.0%. Cash stands at $264.7 million. Guides $130-135 million revenue for 2026.
8-K
FDA warning letter issued
Beta Bionics received an FDA warning letter on January 29, 2026, citing deficiencies in its Quality Management System, Medical Device Reporting, and Correction and Removals from a June 2025 Irvine facility inspection. No production or marketing restrictions apply. Company acts swiftly on fixes. Guidance for Mint launch by end-2027 holds firm, but FDA satisfaction isn't assured.
8-K
Q4 sales up 56% to $32M+
Beta Bionics released preliminary Q4 2025 topline results on January 8, 2026, projecting net sales of at least $32.0 million, up 56% from $20.4 million in Q4 2024. DME channel sales hit at least $22.3 million (up 23%), while PBP surged to $9.7 million (up 308%). Installed base nears 35,000 users. Numbers preliminary; full results February 17.
8-K
Q3 sales up 63%
Beta Bionics reported Q3 net sales of $27.3 million, up 63% from $16.7 million last year, driven by 5,334 new patient starts—a 68% jump. Gross margin expanded to 55.5%, yet operating loss widened to $17.0 million amid heavy sales investment. Sales explode. Company raised 2025 revenue guidance above $96.5 million, targeting 27-29% PBP-reimbursed starts.
ABT
Abbott Laboratories
126.86-1.61
BDX
Becton, Dickinson and Company
196.39-3.70
BMRA
Biomerica, Inc.
2.37-0.08
BSX
Boston Scientific Corporation
92.95+0.76
DXCM
DexCom, Inc.
66.37+0.64
MDT
Medtronic plc.
97.72-0.85
MODD
Modular Medical, Inc.
0.34-0.03
PODD
Insulet Corporation
288.73-2.78
SENS
Senseonics Holdings, Inc.
6.62-0.17
TNDM
Tandem Diabetes Care, Inc.
22.60+0.49